Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952030907> ?p ?o ?g. }
- W2952030907 endingPage "811" @default.
- W2952030907 startingPage "811" @default.
- W2952030907 abstract "Magnetic resonance imaging (MRI) guidance improves the accuracy of prostate biopsy for the detection of clinically significant prostate cancer, but the optimal use of such guidance is not yet clear.To determine the cancer detection rate (CDR) of targeting MRI-visible lesions vs systematic prostate sampling in the diagnosis of clinically significant prostate cancer in men who were biopsy naive.This paired cohort trial, known as the Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) study, was conducted in an academic medical center from January 2015 to April 2018. Men undergoing first-time prostate biopsy were enrolled. Paired-cohort participants were a consecutive series of men with MRI-visible lesions (defined by a Prostate Imaging Reporting & Data System version 2 score ≥ 3), who each underwent 3 biopsy methods at the same sitting: first, a systematic biopsy; second, an MRI-lesion biopsy targeted by cognitive fusion; and third, an MRI-lesion targeted by software fusion. Another consecutive series of men without MRI-visible lesions underwent systematic biopsies to help determine the false-negative rate of MRI during the trial period.The primary end point was the detection rate of clinically significant prostate cancer (Gleason grade group ≥2) overall and by each biopsy method separately. The secondary end points were the effects of the Prostate Imaging Reporting & Data System version 2 grade, prostate-specific antigen density, and prostate volume on the primary end point. Tertiary end points were the false-negative rate of MRI and concordance of biopsy-method results by location of detected cancers within the prostate.A total of 300 men participated; 248 had MRI-visible lesions (mean [SD] age, 65.5 [7.7] years; 197 were white [79.4%]), and 52 were control participants (mean [SD] age, 63.6 [5.9] years; 39 were white [75%]). The overall CDR was 70% in the paired cohort group, achieved by combining systematic and targeted biopsy results. The CDR by systematic sampling was 15% in the group without MRI-visible lesions. In the paired-cohort group, CDRs varied from 47% (116 of 248 men) when using cognitive fusion biopsy alone, to approximately 60% when using systematic biopsy (149 of 248 men) or either fusion method alone (154 of 248 men), to 70% (174 of 248 men) when combining systematic and targeted biopsy. Discordance of tumor locations suggests that the different biopsy methods detect different tumors. Thus, combining targeting and systematic sampling provide greatest sensitivity for detection of clinically significant prostate cancer. For all biopsy methods, the Prostate Imaging Reporting & Data System version 2 grade and prostate-specific antigen density were directly associated with CDRs, and prostate volume was inversely associated.An MRI-visible lesion in men undergoing first-time prostate biopsy identifies those with a heightened risk of clinically significant prostate cancer. Combining targeted and systematic biopsy offers the best chances of detecting the cancer." @default.
- W2952030907 created "2019-06-27" @default.
- W2952030907 creator A5002667725 @default.
- W2952030907 creator A5003945364 @default.
- W2952030907 creator A5028893537 @default.
- W2952030907 creator A5037769555 @default.
- W2952030907 creator A5047802942 @default.
- W2952030907 creator A5051647634 @default.
- W2952030907 creator A5052198650 @default.
- W2952030907 date "2019-09-01" @default.
- W2952030907 modified "2023-10-09" @default.
- W2952030907 title "Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive" @default.
- W2952030907 cites W1545430154 @default.
- W2952030907 cites W1827911007 @default.
- W2952030907 cites W1973034389 @default.
- W2952030907 cites W2019597341 @default.
- W2952030907 cites W2048714893 @default.
- W2952030907 cites W2086308925 @default.
- W2952030907 cites W2097325625 @default.
- W2952030907 cites W2115726304 @default.
- W2952030907 cites W2138237120 @default.
- W2952030907 cites W2146373036 @default.
- W2952030907 cites W2153860297 @default.
- W2952030907 cites W2157814660 @default.
- W2952030907 cites W2165050132 @default.
- W2952030907 cites W2230472428 @default.
- W2952030907 cites W2272450061 @default.
- W2952030907 cites W2334235689 @default.
- W2952030907 cites W2577453388 @default.
- W2952030907 cites W2612386972 @default.
- W2952030907 cites W2735257693 @default.
- W2952030907 cites W2754940790 @default.
- W2952030907 cites W2756318850 @default.
- W2952030907 cites W2789982652 @default.
- W2952030907 cites W2792902150 @default.
- W2952030907 cites W2793905111 @default.
- W2952030907 cites W2894063801 @default.
- W2952030907 cites W2900548778 @default.
- W2952030907 cites W2901859788 @default.
- W2952030907 cites W4251121339 @default.
- W2952030907 doi "https://doi.org/10.1001/jamasurg.2019.1734" @default.
- W2952030907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6563598" @default.
- W2952030907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31188412" @default.
- W2952030907 hasPublicationYear "2019" @default.
- W2952030907 type Work @default.
- W2952030907 sameAs 2952030907 @default.
- W2952030907 citedByCount "105" @default.
- W2952030907 countsByYear W29520309072019 @default.
- W2952030907 countsByYear W29520309072020 @default.
- W2952030907 countsByYear W29520309072021 @default.
- W2952030907 countsByYear W29520309072022 @default.
- W2952030907 countsByYear W29520309072023 @default.
- W2952030907 crossrefType "journal-article" @default.
- W2952030907 hasAuthorship W2952030907A5002667725 @default.
- W2952030907 hasAuthorship W2952030907A5003945364 @default.
- W2952030907 hasAuthorship W2952030907A5028893537 @default.
- W2952030907 hasAuthorship W2952030907A5037769555 @default.
- W2952030907 hasAuthorship W2952030907A5047802942 @default.
- W2952030907 hasAuthorship W2952030907A5051647634 @default.
- W2952030907 hasAuthorship W2952030907A5052198650 @default.
- W2952030907 hasBestOaLocation W29520309071 @default.
- W2952030907 hasConcept C121608353 @default.
- W2952030907 hasConcept C126322002 @default.
- W2952030907 hasConcept C126838900 @default.
- W2952030907 hasConcept C141071460 @default.
- W2952030907 hasConcept C143409427 @default.
- W2952030907 hasConcept C160798450 @default.
- W2952030907 hasConcept C188816634 @default.
- W2952030907 hasConcept C203092338 @default.
- W2952030907 hasConcept C2775934546 @default.
- W2952030907 hasConcept C2776235491 @default.
- W2952030907 hasConcept C2780192828 @default.
- W2952030907 hasConcept C2781217009 @default.
- W2952030907 hasConcept C535046627 @default.
- W2952030907 hasConcept C71924100 @default.
- W2952030907 hasConceptScore W2952030907C121608353 @default.
- W2952030907 hasConceptScore W2952030907C126322002 @default.
- W2952030907 hasConceptScore W2952030907C126838900 @default.
- W2952030907 hasConceptScore W2952030907C141071460 @default.
- W2952030907 hasConceptScore W2952030907C143409427 @default.
- W2952030907 hasConceptScore W2952030907C160798450 @default.
- W2952030907 hasConceptScore W2952030907C188816634 @default.
- W2952030907 hasConceptScore W2952030907C203092338 @default.
- W2952030907 hasConceptScore W2952030907C2775934546 @default.
- W2952030907 hasConceptScore W2952030907C2776235491 @default.
- W2952030907 hasConceptScore W2952030907C2780192828 @default.
- W2952030907 hasConceptScore W2952030907C2781217009 @default.
- W2952030907 hasConceptScore W2952030907C535046627 @default.
- W2952030907 hasConceptScore W2952030907C71924100 @default.
- W2952030907 hasIssue "9" @default.
- W2952030907 hasLocation W29520309071 @default.
- W2952030907 hasLocation W29520309072 @default.
- W2952030907 hasLocation W29520309073 @default.
- W2952030907 hasLocation W29520309074 @default.
- W2952030907 hasOpenAccess W2952030907 @default.
- W2952030907 hasPrimaryLocation W29520309071 @default.
- W2952030907 hasRelatedWork W1606407388 @default.
- W2952030907 hasRelatedWork W2075763133 @default.